Literature DB >> 15811457

Does DOTS work in populations with drug-resistant tuberculosis?

Kathryn DeRiemer1, Lourdes García-García, Miriam Bobadilla-del-Valle, Manuel Palacios-Martínez, Areli Martínez-Gamboa, Peter M Small, José Sifuentes-Osornio, Alfredo Ponce-de-León.   

Abstract

BACKGROUND: Directly observed therapy (DOTS) is the main strategy for prevention and control of tuberculosis worldwide. However, its effect on tuberculosis transmission in populations with moderate rates of drug-resistant disease is not known.
METHODS: This population-based prospective study in southern Mexico between March, 1995, and February, 2000, was based on passive case finding and detection of acid-fast bacilli in sputum samples to diagnose pulmonary tuberculosis. We also used cultures, drug-susceptibility testing, bacterial genotyping, and monitoring of treatment outcomes.
FINDINGS: We enrolled 436 patients; the HIV seroprevalence rate was 2%. We used three indicators to monitor continuing tuberculosis transmission: the incidence rate of pulmonary tuberculosis, which decreased by 54.4% between 1995 and 2000, from 42.1 to 19.2 per 10(5) population (p=0.00048); the percentage of clustered pulmonary tuberculosis cases, which decreased by 62.6% from 22% to 8% (p=0.02); and the rate of primary drug resistance, which decreased by 84.0% from 9.4 to 1.5 per 10(5) population (p=0.004). Rates of multidrug-resistant (MDR) tuberculosis also decreased (p<0.0001). The case-fatality ratio was 12% for MDR tuberculosis (five of 41), 7% for strains resistant to at least one drug after exclusion of MDR (four of 55), and 3% for pansusceptible strains (nine of 272). There were 13 treatment failures (11%) in 1995 and one (2%) in 2000 (p=0.012).
INTERPRETATION: Even in settings with moderate rates of MDR tuberculosis, DOTS can rapidly reduce the transmission and incidence of both drug-susceptible and drug-resistant tuberculosis. However, further interventions, such as drug-susceptibility testing and standardised or individualised treatment regimens, are needed to reduce mortality rates for MDR tuberculosis.

Entities:  

Mesh:

Year:  2005        PMID: 15811457     DOI: 10.1016/S0140-6736(05)74812-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  33 in total

1.  Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations.

Authors:  Ted Cohen; Marc Lipsitch; Rochelle P Walensky; Megan Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

2.  Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam.

Authors:  M Caws; Phan Minh Duy; Dau Quang Tho; Nguyen Thi Ngoc Lan; Dai Viet Hoa; Jeremy Farrar
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

3.  Ancillary-care responsibilities in observational research: two cases, two issues.

Authors:  N Dickert; K DeRiemer; P E Duffy; L Garcia-Garcia; T K Mutabingwa; B J Sina; P Tindana; R Lie
Journal:  Lancet       Date:  2007-03-10       Impact factor: 79.321

4.  The long-term health and economic benefits of DOTS implementation in Ecuador.

Authors:  Olivia Oxlade; Judyth Vaca; Elizabeth Romero; Kevin Schwartzman; Brian Graham; Lucero Hernandez; Terry Tannenbaum; Dick Menzies
Journal:  Can J Public Health       Date:  2006 Jan-Feb

Review 5.  Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis.

Authors:  Christopher Dye
Journal:  Nat Rev Microbiol       Date:  2009-01       Impact factor: 60.633

Review 6.  Multidrug-resistant to extensively drug resistant tuberculosis: what is next?

Authors:  Amita Jain; Pratima Dixit
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

7.  Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru.

Authors:  Vivian Kawai; Giselle Soto; Robert H Gilman; Christian T Bautista; Luz Caviedes; Luz Huaroto; Eduardo Ticona; Jaime Ortiz; Marco Tovar; Victor Chavez; Richard Rodriguez; A Roderick Escombe; Carlton A Evans
Journal:  Am J Trop Med Hyg       Date:  2006-12       Impact factor: 2.345

8.  Evaluation of a semi-automated reporter phage assay for susceptibility testing of Mycobacterium tuberculosis isolates in South Africa.

Authors:  Niaz Banaiee; Vanessa January; Charmaine Barthus; Maureen Lambrick; Denise Roditi; Marcel A Behr; William R Jacobs; Lafras M Steyn
Journal:  Tuberculosis (Edinb)       Date:  2007-11-05       Impact factor: 3.131

Review 9.  Tuberculosis: drug resistance, fitness, and strategies for global control.

Authors:  Erik C Böttger; Burkhard Springer
Journal:  Eur J Pediatr       Date:  2007-11-07       Impact factor: 3.183

10.  Drug-resistant tuberculosis in Shanghai, China, 2000-2006: prevalence, trends and risk factors.

Authors:  X Shen; K DeRiemer; Z-An Yuan; M Shen; Z Xia; X Gui; L Wang; Q Gao; J Mei
Journal:  Int J Tuberc Lung Dis       Date:  2009-02       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.